J&J Pulls Simponi Injections for Possible Dosing Defects

Johnson & Johnson has recalled lots of its Simponi injections for possible substandard dosage of its arthritis treatment, according to a Reuters news report.

A Johnson & Johnson spokesperson said there are no quality issues regarding the actual medication Simponi. Rather, a defect in the device did not allow the full dose to be delivered for self-injection. The defect was detected in Germany during quality assurance checks. In total, 165 U.S. units have been recalled, according to the report.

Read the news report about the Johnson & Johnson recall.

Read other coverage about Johnson & Johnson:

- Smith & Nephew Shares Jump After Rejecting Johnson & Johnson Acquisition

- Alphatec Holdings Names Former Johnson & Johnson CFO as New CFO

- FDA Sends Johnson & Johnson Letter of Warning

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers